This paper is motivated by a phase I-II clinical trial of a targeted agent for advanced solid tumors. We study a stylized version of this trial with the goal to determine optimal actions in each of two cycles of therapy. A design is presented that generalizes the decision-theoretic two-cycle design of Lee and others (2015. Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity. Journal of the American Statistical Association, to appear) to accommodate ordinal outcomes. Backward induction is used to jointly optimize the actions taken for each patient in each of the two cycles, with the second action accounting for the patient's cycle 1 dose and outcomes. A simulation study shows that simpler designs obtained by dichotomizing the ordinal outcomes either perform very similarly to the proposed design, or have much worse performance in some scenarios. We also compare the proposed design with the simpler approaches of optimizing the doses in each cycle separately, or ignoring the distinction between cycles 1 and 2.
INTRODUCTION AND MOTIVATION
This paper is motivated by the problem of designing a dose-finding trial of a new agent for cancer patients with advanced solid tumors. The agent aims to inhibit a kinase, which regulates cell metabolism and 306 J. LEE AND OTHERS ordinal toxicity designs are not substantial in comparison to binary toxicity designs. However, the comparison looks quite different for the model-based two-cycle design for bivariate ordinal (efficacy, toxicity) outcomes that we propose in this paper. In simulations described in Section 4.4, we compare the proposed design with designs that do not properly model association between cycles. In simulations reported in Section 4.5, we show that the use of ordinal rather than binary outcomes can substantially improve design performance in our setting.
Section 2 describes the proposed decision-theoretic method for ordinal outcomes in two cycles (DTD-O2). Sections 3 and 4 include decision criteria using utilities and a simulation study. The last section concludes with a final discussion.
A DECISION-THEORETIC DESIGN

Actions and optimal sequential decisions
For notational convenience, we denote the possible levels of toxicity by 0, 1, . . . , J − 1 and efficacy by 0, 1, . . . , K − 1. For the motivating trial, these are Y = 0 for None/Mild, 1 for Moderate, and 2 for Severe, and Z = 0 for PD, 1 for SD, and 2 for CR/PR, so K = J = 3. If the adaptively chosen cycle 1 action d 1 = NT for any patient, then the trial is stopped and no more patients are enrolled. Otherwise, the patient receives a dose d 1 of the agent in cycle 1. A cycle 2 action is a function mapping the cycle 1 dose and outcomes, We apply a Bayesian decision-theoretic paradigm to determine an optimal decision rule. First, focus on cycle 1, and temporarily ignore cycle 2. The general setup of a Bayesian decision problem involves actions d 1 , observable data y = (Y 1 , Z 1 ), parameters θ that index a sampling model p(y | θ, d 1 ) for the data, and a prior probability model p(θ ) for the parameters. We discuss specification of D in more detail below. A utility function u(d 1 , θ, y) formalizes relative preferences for alternative actions under hypothetical outcomes y and assumed truth θ . Starting from first principles, one can then argue (Robert, 2007, Chapter 2) that a rational decision-maker chooses the action d 1 that maximizes utility in expectation, that is
The integral is the expected utility U 1 (d 1 ) = E y,θ {u(d 1 , θ, y)}, with the expectation taken with respect
To simplify notation, we will henceforth suppress conditioning on X n in the notation.
In the two-cycle dose-finding problem, the sequential nature of the within-patient decisions complicates the solution. In the second cycle, the utility u(d 1 , θ, y) is replaced by the expected utility under optimal continuation. Denote y 1 = (Y 1 , Z 1 ) and y 2 = (Y 2 , Z 2 ). We get an alternating sequence of optimization and expectation with the second cycle expected total utility as a function of y 1 ) and take the expectation with respect to y 1 we obtain
which is maximized to determine the optimal decision for cycle 1,
. This alternating sequence of maximization and expectation, called dynamic programming, is characteristic of sequential decision problems. While it often leads to intractable computational problems (Parmigiani and Inoue, 2009, Chapter 12) , in the present setting with ordinal outcomes the problem is solvable. Dynamic programming recently has been applied in other clinical trial design settings (Murphy, 2003; Zhao and others, 2011; Lee and others, 2015; Cheung and others, 2014) .
Utility function
We construct a utility function
as a sum over cycle-specific utilities u cycle (Y c , Z c ), c = 1, 2, where 0 λ 1 is a scale parameter. If λ = 0, then the cycle 2 utility is ignored in selecting d 1 , while λ = 1 corresponds to treating utilities in the two cycles equally. Optimal decisions may change under different values of λ. Even with λ = 0, however, the importance of jointly modeling the two cycles remains in that inference on θ can be enhanced through borrowing information across cycles. For the simulations in Section 4, we used λ = 0.8. A sensitivity analysis in λ is reported in the Supplementary Materials (available at Biostatistics online). The utility function (2.4) focuses on the clinical outcomes and is a function of (y 1 ,
That is, the inference on θ does not affect utility, and we do not initially consider preferences across doses d c . We thus drop θ and d c from the arguments of u cycle (·) hereafter. In practice, numerical utilities of the J × K elementary must be elicited from the clinical collaborators, with specific numerical values reflecting physicians' relative preferences (cf. Thall and Nguyen, 2012) . In our stylized illustrative trial, we fix the utilities of the best and worst possible outcomes to be u cycle (0, K − 1) = 100 and u cycle (J − 1, 0) = 0. In general, any convenient function with u cycle ( j, k − 1) < u cycle ( j, k) and u cycle ( j, k) > u cycle ( j + 1, k) that gives higher utilities to more desirable outcomes may be used. For future reference, we note that u cycle (0, 0) is the expected utility corresponding to NT, i.e. do not treat the patient. Table 1 shows the utilities that will be used for our simulation studies.
To reduce notation, we denote the utility u(y 1 , y 2 ) as a function of hypothetical outcomes (y 1 , Z 1 ) . Assuming that the utility function takes the additive form (2.4), we define cycle-specific expected utilities, with the expected utility for cycle 2 given bỹ
(2.5) Some practical guidelines of using utility functions for a design with ordinal outcomes in the two-cycle setting are provided in Section 1 of the Supplementary Material (available at Biostatistics online).
Action set
Equation (2.2) includes two maximizations to determine d 1 and d 2 . In the discussion thus far, we have not used the particular elements of D, and they might have been any actions. In actual dose-finding, ethical and practical constraints are motivated by the knowledge that, in general, higher doses carry a higher risk of more severe toxicity. We thus require a more restrictive action set, with additional conditions for the acceptability of a dose assignment.
The first additional criterion is that we do not skip untried dose levels when escalating. This rule is imposed almost invariably in actual trials with adaptive dose-finding methods. Let d At any interim point in the trial, let X denote the current data, including dose assignments for previously enrolled patients. The three conditions together make the action sets for d 1 and d 2 dependent on X , d 1 , and y 1 = (Y 1 , Z 1 ). We let D 1 (X ) and D 2 (d 1 , y 1 , X ) denote the action sets for d 1 and d 2 , respectively, that are implied by these three restrictions.
Inference model
Thus far, our discussion of optimal decisions has not included a particular probability model. We will assume a 4D ordinal probit model for 
) denote a vector of latent probit scores for the ith patient and let {γ y, j } and {γ z,k } denote fixed cutoffs that define 
cycles, the same cutoffs are used for all cycles. The u i,c and v i,c are multivariate normal probit scores, 6) and
. The covariance matrix implies associations across cycles and across outcomes through ρ and τ 2 . Given that the ordinality of the outcomes is accounted for by the latent probit scores and fixed cutoff parameters {γ y, j } and {γ z,k }, a simple yet flexible model for regression 310 J. LEE AND OTHERS on dose is obtained by assuming μ xcd = β xc0 + β xc1 d β xc2 c with x = u for toxicity and x = v for efficacy. A discussion of nonlinear dose-response models is given by Bretz and others (2005) . We assume that the toxicity and efficacy probabilities increase monotonic in dose by requiring β xc1 > 0 and β xc2 > 0. Denote β xc = (β xc0 , log β xc1 , log β xc2 ), x = u, v and c = 1, 2. We complete the model with a normal prior
TRIAL DESIGN
Adaptive randomization
Although, in terms of the utility-based objective function, d yields the best clinical outcomes for the next patient, the performance of the design, in terms of frequentist operating characteristics, can be improved by including adaptive randomization (AR) among actions giving values of the objective function near the maximum at d . Using AR decreases the probability of getting stuck at a suboptimal d, and also has the effect of treating more patients at doses having larger utilities, on average. The problem that a "greedy" search algorithm may get stuck at suboptimal actions, and the simple solution of introducing additional randomness into the search process, are well known in the optimization literature (cf. Tokic, 2010) . This has been dealt with only very recently in dose-finding (Bartroff and Lai, 2010; Azriel and others, 2011; Braun and others, 2012; Thall and Nguyen, 2012) .
To implement AR, we first define i to be a function decreasing in patient index i, and denote = ( 1 , . . . , n ). We define the set of i -optimal doses for cycle 1 to be
is within i of the maximum posterior mean utility. Similarly, we define the set of ( i /2)-optimal doses for cycle 2 given (d i,1 , y i,1 ) to be
is based on (2.5). Our design randomizes patients uniformly among doses in D i,1 for c = 1 and D i,2 for c = 2, which we call AR( ). Numerical values of i depend on the range of u cycle (y, z), and are determined by preliminary trial simulations in which is varied.
Illustrative trial
Our illustrative trial studied in the simulations is a stylized version of the phase I-II chemotherapy trial with five dose levels described in Section 1, but here accounting for two cycles of therapy. The maximum sample size is 60 patients with a cohort size of 2. Based on preliminary simulations, we set i = 20 for the first 10 patients, i = 15 for the next 10 patients, and i = 10 for the remaining 40 patients. An initial cohort of 2 patients is treated at the lowest dose level in cycle 1, their cycle 1 toxicity and efficacy outcomes are observed, the posterior of β xc , x = u, v and c = 1, 2 is computed, and actions are taken for cycle 2 of the initial cohort. If D i,2 = {NT}, then patient i does not receive a second cycle of treatment. If D i,2 | ={NT}, then AR( ) is used to choose an action for cycle 2 from D i,2 \ {NT}. When the toxicity and efficacy outcomes are observed from cycle 2, the posterior of β xc is updated. The second cohort is not enrolled until the first cohort has been evaluated for cycle 1. For all cohorts after the first, after the outcomes of all previous cohorts are observed, the posterior is updated, the posterior expected utility, U 1 (d 1 ) is computed using λ = 0.8, and D 1 (X ) is determined. Using D 1 (X ) and i , we find and d 2 (d 1 , y 1 ) as optimal policy d 2,sel (d 1 , y 1 ) . If the trial is early terminated, let d 1,sel = NT and d 2,sel = NT for all y 1 .
SIMULATION STUDY
Designs for comparison
Let DTD-O2 denote the proposed decision-theoretic two-cycle design. We compare DTD-O2 with three other designs. The first is obtained by reducing each 3-level efficacy and toxicity outcome to a 2-category (binary) variable by combining categories, but using the same probability model to ensure a fair comparison. The next two comparators are single cycle designs. The first, called Single Cycle Comparator 1 (SCC1), assumes no association between cycles and optimizes d 1 and d 2 separately. The second, called Single Cycle Comparator 2 (SCC2), does not distinguish between cycles and treats the two cycles identically.
For SCC1, we assume patient-specific random probit scores, independent over cycles,
and 11 is the 2 × 2 covariance matrix. We let 11 be the upperleft partition of in (2.6). Owing to the independence of probit scores over cycles within a patient, SCC1 models the association between Y c and Z c within the same cycle only and does not assume any association between outcomes in different cycles, for example, Y 1 and Y 2 . The other model specification including the regression of μ dc on the dose in Section 2.4 stays the same. For SCC2, in addition to having patient-and cycle-specific random probit scores as in SCC1, we assume that the mean dose effects are identical in the two cycles by dropping the cycle index from β in Section 2.4, i. 
Simulation setup
We simulated trials under each of 8 scenarios using each of the designs. A total of N = 1000 trials were simulated for each design under each scenario. The simulation scenarios were determined by fixing a set of marginal probabilities and regression coefficients on probit scores, given in Table 2 and Supplementary  Material Table S1 (available at Biostatistics online). Each simulation scenario is specified by the marginal distributions of Y and Z . Table 2 gives the true
, where is the cumulative distribution function of the standard normal distribution. To ensure a fair comparison, we intentionally define a simulation truth that is different from the assumed model used by the design methodology. The simulation model is best described as a generative model, first for Y 1 , then Z 1 given Y 1 , and then (Y 2 , Z 2 ) given Y 1 , Z 1 . Generating Y 1 : We first generate Y 1 from the distribution specified by P( 
For later use, we defineZ by rescaling Z to be evenly spaced in
Here 
where w 3,1 , w 3,3 0 and w 3,2 , w 3,4 0. Similar to r T , r E determines a joint effect of d 1 and Z 1 on Z 2 . The detailed specification of the coefficients, r T and r E for each simulation scenario is described in the Supplementary Materials (available at Biostatistics online). Table 3 shows the optimal actions, d 1 and
, over two cycles under each of the 8 simulation scenarios under the simulation truth. For example, in Scenario 3, the optimal cycle 1 action is to give dose level 3, and the optimal cycle 2 action is to treat patients with Y 1 = 0 at d 2 = 4, and at d 2 = 2 if Y 1 = 1.
We calibrate the fixed hyperparameters,θ = (σ
, for x = u, v and c = 1, 2 and the cutoff points, (γ y , γ z ), using effective sample size (ESS), described in the Supplementary Materials (available at Biostatistics online). We setθ and the cutoffs, γ x and γ y , and simulate 1000 pseudo-samples ofβ x,c , x,c , x = u, v and c = 1, 2. We then compute probabilities of interest based on the pseudo-samples,
For all simulations, we determinedθ to give each prior 314 J. LEE AND OTHERS ESS between 0.5 and 2, using the approximation obtained by matching moments with a Dirichlet distribution. We used the sameθ for SCC1 and SCC2.
Evaluation criteria
We evaluate design performance for the patients treated in the trial using three different summary statistics,ū,Ū trt , andŪ sel . Recall that in a trial we record the clinical outcomes of the n patients with their assigned doses and recommended doses for future patients, y i,c = (Y i,c , Z i,c ), d ic , i = 1, . . . , n and  c = 1, 2, and (d 1,sel , d 2,sel (d 1,sel , Y 1 , Z 1 ) ), respectively. We index the N simulated replications of the trial by = 1, . . . , N . We define average utility for the n patients in the th simulated trial in two different ways; 
One may regardū andŪ trt as indexes of the ethical desirability of the method, given u cycle (y, z). The proposed method gives an optimal action d 1,sel for cycle 1, and policy d 2,sel for cycle 2. We let 
That is the expected utility with respect to the assumed distribution of y 1 when d 1,sel is given. 0, 0) . This expectation is computed under the distribution of y 1 given d 1,sel . If the rule d 2,sel is used, the expected cycle 2 payoff is
where
The total expected payoff to a future patient treated using the optimal regime
Comparison to designs with binary outcomes
We first compare DTD-O2 with designs obtained by collapsing each trinary toxicity and efficacy outcome to a binary variable. This mimics what often is done in practice in order to apply a phase I-II design based on binary efficacy and toxicity. We use an appropriately reduced version of our assumed underlying model to ensure a fair comparison. Since this reduction is not unique, we exhaustively define binary outcomes in four different ways, binary cases 1-4, given in Section 4 of the Supplementary Material (available at Biostatistics online). The utilities associated with the binary outcomes are defined accordingly based on the utilities in Table 1 . The results, in terms ofū,Ū trt , and U sel , are summarized graphically in Figure 2 . Scenario 8 is not included in Figure 2 because the optimal action is NT in both cycles, and in this case all designs stop the trial early with high probability, The figure shows that reducing to binary outcomes can produce designs with much worse performance than DTD-O2, while for some cases the performance may be comparable. The binary outcome design's performance also varies substantially with the particular dichotomization used. Since different physicians may combine ordinal categories in different ways, the practical implication is that the additional complexity of the ordinal outcome design is worthwhile, in terms of benefit to both the patients treated in the trial and future patients.
Comparison to single cycle designs
The simulation results for DTD-O2, SCC1, and SCC2 are summarized in Figure 3 . Scenarios 1-4 have the same marginal toxicity and efficacy probabilities, but different values of coefficients (w), yielding different probit scores and different association structures of d 1 , y 1 , d 2 , and y 2 . Scenario 1 has large w 2,2 and w 3,2 , so that the cycle 1 toxicity outcome greatly affects cycle 2 expected utilities in the simulation truth. As shown in Table 3 , the optimal action in cycle 2 after observing severe toxicity in cycle 1 is NT regardless of the cycle 1 efficacy outcome. Scenario 4 is similar to Scenario 1 but the cycle 1 efficacy outcome heavily affects the cycle 2 treatment in that all cycle 2 treatments are less desirable than NT when PD is observed in cycle 1. In Scenarios 2 and 3, the two cycle 1 outcomes jointly determine the cycle 2 treatment as shown in the tables. Scenario 3 has larger association between Y c and Z c within each cycle. In Scenarios 1-4, modeling dependence across cycles improves the performance, as shown in Figure 3 , where DTD-O2 is superior to SCC1 and SCC2 in terms of all the three criteria,ū,Ū trt , and U sel . Since the only difference between DTD-O2 and SCC1 is whether the two cycles are modeled jointly or separately, the results show that the joint modeling significantly improves the performance. Differences in the performance are smaller for Scenarios 1 and 4. This may be because the true structure that one cycle 1 outcome dominates cycle 2 decisions in the scenarios is not easily accommodated under the assumed covariance structure in (2.6) and each trial gets only a small number of patients. In such a case, separate estimation for the two cycles may not be a very poor approach. In addition, the three methods are compared usingū andŪ trt based on the last 20 patients in each trial for the three designs (not shown). This comparison shows that the improvement by DTD-O2 over the other two methods becomes greater, especially for Scenarios 1 and 4. It may imply that learning takes more patients for DTD-O2 when there is a discrepancy between the truth and the model assumption. Scenarios 5-7 have different shapes for U 1 (d 1 ) as a function of d 1 . The cycle 1 utilities are U-shaped in Scenario 5, monotone increasing in Scenario 6, and monotone decreasing in Scenario 7. Very mild associations between outcomes and between cycles are assumed for these scenarios. For Scenarios 5 and 6, DTD-O2 achieves notably better performance (see Figure 3 ), withū and U sel similar to each other for DTD-O2. This implies that DTD-O2 identifies desirable actions early in the trial, treats many of the patients with the desirable actions, and has a high probability of selecting truly optimal actions at the end of a trial. In Scenario 7, DTD-O2 shows slightly worse performance (see the rightmost of Figure 3 ). In the simulation truth of Scenario 7, the cycle 1 expected utility does not change much with d 1 , but the cycle 2 expected utility is very sensitive to d 1 , Y 1 , and Z 1 . This is a very challenging case for DTD-O2, and not modeling dependence between the cycles leads to better performance than incorrectly modeling in this particular scenario. Scenario 8 has no acceptable dose in either cycle. All the three methods terminate the trials with probability 1 in this case, with mean sample sizes 9.11, 8.33, and 8.29 .
In all 8 scenarios, SCC2 yields better results than SCC1. This may be because d 2 and d 1 happen to be identical in many cases, so combining outcomes from the two cycles works well. However, the results for Scenarios 1-4 show that using each patient's cycle 1 dose and outcomes to select d 2 gives significantly superior performance in cases where there is significant dependence between the two cycles. More results are summarized using empirical toxicity and efficacy probabilities in Section 3 of Supplementary Material (available at Biostatistics online).
We carried out a sensitivity analysis in λ, under Scenarios 2 and 5, including the four binary outcome designs, SCC1, SCC2, and DTD-O2, for λ = 0.0, 0.4, 0.8, and 1.0. The results, given in Section 5 of Supplementary Material (available at Biostatistics online), show that changes in design performance with λ are very small, but λ = 0, corresponding to no use of cycle 2 utility in making a decision at cycle 1, yields higher early termination probabilities for binary outcome cases 1 and 3.
DISCUSSION
We have extended the decision-theoretic two-cycle phase I-II dose-finding method in Lee and others (2015) to accommodate ordinal outcomes. Our simulations show that incorporating cycle 1 information into the cycle 2 treatment decision yields good performance for both patients treated in a trial and future patients. The simulations in Figure 2 show that this extension may greatly improve design performance, quantified byū,Ū trt , and U sel , compared with using binary toxicity and efficacy indicators. The proposed model and method also compared quite favorably with either assuming the two cycles are independent or ignoring the distinction between cycles 1 and 2.
In theory, DTD-O2 could be extended to more than two cycles. For this to be tractable, additional modeling assumptions may required to control the number of parameters, since decisions must be made
